Becker Cordelia, Heidersdorf Stefan, Drewlo Sascha, de Rodriguez Sonja Zirke, Krämer Juergen, Willburger Roland Ernst
Department of Orthopaedic Surgery, St. Josef-Hospital, University of Bochum, Bochum, Germany.
Spine (Phila Pa 1976). 2007 Aug 1;32(17):1803-8. doi: 10.1097/BRS.0b013e3181076514.
Prospective, double-blind, reference-controlled, investigator-initiated, single center.
To evaluate the efficacy of Autologous Conditioned Serum (ACS; Orthokine) for the treatment of lumbar radicular compression in comparison to triamcinolone.
Evidence from animal studies indicates that cytokines such as interleukin-1 play a decisive role in the pathophysiology of lumbar radiculopathy. ACS is enriched in the interleukin-1 receptor antagonist and other anti-inflammatory cytokines.
Thirty-two patients were treated by epidural perineural injections with ACS; 27 patients were treated with 5 mg triamcinolone and 25 patients with 10 mg triamcinolone. Treatment was applied once per week for 3 consecutive weeks and followed for 6 months. The Visual Analogue Scale (VAS) of low back pain was the primary outcome measure. The Oswestry Disability Index (ODI) was the secondary endpoint of the study. All statistical analyses were performed in an exploratory manner using SAS for Windows, version 8.2, on a personal computer. Descriptive statistics were calculated for the VAS and ODI by treatment group and time point. The data were submitted to a repeated-measurements analysis of variance with effects on treatment group, time, and treatment group-by-time interaction.
Patients with lumbar back pain who were treated with ACS or the 2 triamcinolone concentrations showed a clinically remarkable and statistically significant reduction in pain and disability, as measured by patient administered outcome measurements. From Week 12 to the final evaluation at Week 22, injections with ACS showed a consistent pattern of superiority over both triamcinolone groups with regard to the VAS score for pain, but statistical significance was observed only at Week 22 in direct comparison to the triamcinolone 5 group. However, there was no statistically significant difference between the 2 triamcinolone dosages during the 6 months of the study.
ACS is an encouraging treatment option for patients with unilateral lumbar radicular compression. The decrease in pain was pronounced, clinically remarkable, and potentially superior to steroid injection.
前瞻性、双盲、对照、研究者发起的单中心研究。
比较自体条件血清(ACS;Orthokine)与曲安奈德治疗腰椎神经根受压的疗效。
动物研究证据表明,白细胞介素-1等细胞因子在腰椎神经根病的病理生理学中起决定性作用。ACS富含白细胞介素-1受体拮抗剂和其他抗炎细胞因子。
32例患者接受硬膜外神经周围注射ACS治疗;27例患者接受5mg曲安奈德治疗,25例患者接受10mg曲安奈德治疗。每周治疗1次,连续3周,随访6个月。腰痛视觉模拟量表(VAS)是主要结局指标。Oswestry功能障碍指数(ODI)是研究的次要终点。所有统计分析均在个人计算机上使用Windows版SAS 8.2进行探索性分析。按治疗组和时间点计算VAS和ODI的描述性统计量。数据进行重复测量方差分析,分析治疗组、时间以及治疗组与时间的交互作用。
接受ACS或两种曲安奈德浓度治疗的腰痛患者,通过患者自我管理的结局测量,疼痛和功能障碍在临床上有显著且统计学上有意义的减轻。从第12周到第22周的最终评估,在疼痛VAS评分方面,ACS注射显示出始终优于两个曲安奈德组的模式,但仅在第22周与曲安奈德5mg组直接比较时观察到统计学意义。然而,在研究的6个月期间,两种曲安奈德剂量之间没有统计学显著差异。
ACS是单侧腰椎神经根受压患者令人鼓舞的治疗选择。疼痛减轻明显,临床上显著,可能优于类固醇注射。